Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

This study is testing a combination of two immunotherapy drugs — durvalumab and tremelimumab — as a first-line treatment for Chinese patients with advanced liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed. **You may be eligible if:** - You have been diagnosed with liver cancer (HCC) confirmed by tissue biopsy or imaging - You have not previously received any systemic treatment for HCC - Your cancer is at an advanced stage (BCLC B not suitable for local treatment, or BCLC C) - Your liver function is reasonably preserved (Child-Pugh class A or B) - You have at least one measurable tumor **You may NOT be eligible if:** - You had a brain episode related to liver disease (hepatic encephalopathy) in the last 12 months - You have significant fluid buildup in your abdomen (clinically meaningful ascites) - You have a blood clot in your main portal vein from the tumor - You have had active bleeding from the gut (such as esophageal varices) in the last 6 months - You have both hepatitis B and hepatitis C, or both hepatitis B and hepatitis D Talk to your doctor to see if this trial is right for you.